Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Accumulated Expenses (2016 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Accumulated Expenses for 10 consecutive years, with $61.1 million as the latest value for Q2 2025.

  • On a quarterly basis, Accumulated Expenses fell 60.46% to $61.1 million in Q2 2025 year-over-year; TTM through Jun 2025 was $61.1 million, a 60.46% decrease, with the full-year FY2024 number at $241.0 million, up 190.55% from a year prior.
  • Accumulated Expenses was $61.1 million for Q2 2025 at Ultragenyx Pharmaceutical, down from $241.0 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $241.0 million in Q4 2024 to a low of $47.9 million in Q2 2022.
  • A 5-year average of $104.5 million and a median of $78.9 million in 2022 define the central range for Accumulated Expenses.
  • Peak YoY movement for Accumulated Expenses: surged 249.92% in 2023, then tumbled 60.46% in 2025.
  • Ultragenyx Pharmaceutical's Accumulated Expenses stood at $62.6 million in 2021, then rose by 26.12% to $78.9 million in 2022, then grew by 5.06% to $82.9 million in 2023, then soared by 190.55% to $241.0 million in 2024, then crashed by 74.66% to $61.1 million in 2025.
  • Per Business Quant, the three most recent readings for RARE's Accumulated Expenses are $61.1 million (Q2 2025), $241.0 million (Q4 2024), and $185.0 million (Q3 2024).